Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).
Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, Molinier O, Özgüroğlu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW.
Levy B, et al. Among authors: voccia i.
Lung Cancer. 2022 Apr;166:107-113. doi: 10.1016/j.lungcan.2022.01.023. Epub 2022 Feb 3.
Lung Cancer. 2022.
PMID: 35257949
Free article.
Clinical Trial.